amgen meritade glp-1 activity duration aims to enter weight loss drug market with a new approach Amgen's peek at its GLP-1

Early studies suggest GLP-1 receptor agonists may reduce inflammatory markers in the brain, creating a more protective environment for neurons

STEP-1 Trial (Semaglutide 2.4 mg, N=1,961) The STEP-1 trial published in the New England Journal of Medicine reported that among participants receiving semaglutide 2.4 mg subcutaneously once weekly, nausea occurred in 44.2%, diarrhea in 29.7%, vomiting in 24.5%, and constipation in 24.1%, compared to 16.0%, 15.9%, 6.8%, and 11.1% with placebo, respectively [3]

We excluded publications prior to 2013, non-English articles, case reports, conference abstracts, editorials, and studies lacking sufficient bone-related data

The sample size was relatively small